Skip to main content

Amyotrophic Lateral Sclerosis (ALS) and cannabis in Iowa

The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Listed qualifying condition
✓ Yes
LEGAL
Capped at 4.5 grams THC…
POSSESSION
$100/yr
STATE FEE
7–21 d
TIMELINE
Listed qualifying condition. The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Iowa statute and program

The Iowa Medical Cannabidiol Program is the operating authority for Iowa patient certification. The authoritative legal text is: Iowa Code Chapter 124E: Medical Cannabidiol Act.

What the evidence says about cannabis and Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that destroys motor neurons in the brain and spinal cord, leading to loss of voluntary muscle control. Symptoms typically include muscle weakness, spasticity, fasciculations, dysphagia, and respiratory compromise. Most patients survive 2–5 years from diagnosis.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Amyotrophic Lateral Sclerosis (ALS) page.

How to qualify in Iowa

The Iowa Medical Cannabidiol Program requires the following registration steps for a Amyotrophic Lateral Sclerosis (ALS) patient (or any qualifying diagnosis):

  1. Get a healthcare-practitioner certification from an Iowa-licensed provider. Under the Iowa Medical Cannabidiol Act (Iowa Code Ch. 124E), any Iowa-licensed physician, advanced registered nurse practitioner, physician assistant, or podiatrist may certify a patient for one of the enumerated debilitating medical conditions: cancer, MS, seizures, Crohn’s, AIDS or HIV, ALS, Parkinson’s, intractable autism, untreatable pain, ulcerative colitis, severe and chronic PTSD, or any terminal illness with a life expectancy of one year or less.
  2. Apply through the Iowa HHS Office of Medical Cannabidiol portal. The patient submits the Healthcare Practitioner Certification and the Patient Application through the Iowa Department of Health and Human Services (HHS) Office of Medical Cannabidiol online portal, uploads an Iowa driver license or state ID, and pays the registration fee.
  3. Pay the $100 state registration fee (or $25 reduced fee). The annual Iowa medical cannabidiol registration card fee is $100, reduced to $25 for patients enrolled in Medicaid, hawk-i, the Family Investment Program, or who have demonstrated household income at or below 200% of the federal poverty level. Caregivers register separately at the same fee structure.
  4. Receive the card and purchase from an Iowa medical cannabidiol dispensary. Iowa medical cannabidiol registration cards are issued within roughly 15 business days of complete application. With the card, patients may purchase capped doses (currently 4.5 grams of THC per 90-day rolling period under §124E.2A) from any of the licensed Iowa medical cannabidiol dispensaries. Permitted forms include capsules, tinctures, topicals, vape products, and sublinguals (no smokable flower under Ch. 124E). Iowa does not honor out-of-state medical cards.
State registration fee
$100
Physician visit (typical)
$150–$300
Certification to card
7–21 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Iowa registration steps, fees, and reciprocity rules, see the Iowa cannabis-laws page.

ICD-10 code

A certifying physician documenting Amyotrophic Lateral Sclerosis (ALS) for the Iowa medical cannabis program will typically record ICD-10 G12.21 or SNOMED-CT 86044005 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Iowa list Amyotrophic Lateral Sclerosis (ALS) as a qualifying condition for medical cannabis?

Yes. Iowa explicitly lists Amyotrophic Lateral Sclerosis (ALS) as a qualifying condition under Iowa Medical Cannabidiol Program. A patient with a documented Amyotrophic Lateral Sclerosis (ALS) diagnosis can pursue state-program certification with a physician registered in the state. The qualifying-condition list is set by state statute or regulation and may change. Inclusion on the list does not guarantee certification — a physician still has to evaluate the patient and decide that medical cannabis is appropriate for that specific case under Iowa rules.

How do I get a Iowa medical marijuana card for Amyotrophic Lateral Sclerosis (ALS)?

Step one is finding a physician licensed in Iowa who is registered with Iowa Medical Cannabidiol Program and willing to evaluate Amyotrophic Lateral Sclerosis (ALS) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Iowa does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Amyotrophic Lateral Sclerosis (ALS)?

For Amyotrophic Lateral Sclerosis (ALS), evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Amyotrophic Lateral Sclerosis (ALS) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Amyotrophic Lateral Sclerosis (ALS) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Amyotrophic Lateral Sclerosis (ALS) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Amyotrophic Lateral Sclerosis (ALS); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Iowa Code Chapter 124E: Medical Cannabidiol Actaccessed May 16, 2026
  2. Iowa Department of Health and Human Services: Office of Medical Cannabidiolaccessed May 16, 2026
  3. Wikipedia: Cannabis in Iowaaccessed May 16, 2026
  4. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 15, 2026
  5. ALS Association: Cannabis and ALSaccessed May 15, 2026